A large phase III randomized trial testing Ambrisentan (Letairis) for early idiopathic pulmonary fibrosis was stopped early after an interim analysis of the data showed possible harm.
Ambrisentan (Letairis) stopped early in IPF trial
Ambrisentan (Letairis) stopped early in IPF…
Ambrisentan (Letairis) stopped early in IPF trial
A large phase III randomized trial testing Ambrisentan (Letairis) for early idiopathic pulmonary fibrosis was stopped early after an interim analysis of the data showed possible harm.